Drug Type Small molecule drug |
Synonyms Merestinib (USAN/INN), 5OGS5K699E, LY-2801653 |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC30H22F2N6O3 |
InChIKeyQHADVLVFMKEIIP-UHFFFAOYSA-N |
CAS Registry1206799-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11763 | Merestinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | 11 Nov 2016 | |
Advanced biliary tract cancer | Phase 2 | US | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | AR | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | AU | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | AT | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | BE | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | CZ | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | DK | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | FR | 19 May 2016 | |
Advanced biliary tract cancer | Phase 2 | DE | 19 May 2016 |
Phase 2 | 12 | (NSCLC (Met Exon 14 Mutation)) | riyozmvuiv(rvqwgxbjop) = wddrptjevk kzqhbjghtd (cigpnbfdlo, phrgnxnqut - dbwerasswu) View more | - | 11 Apr 2024 | ||
(Solid Tumor (NTRK1,2,3 Rearrangement)) | sdbzqizuzv(jrucsmvvcz) = pczwqitvbg zwoesylsdx (yeuxbuqlmq, gvvybrjrqp - qhimjpfnri) View more | ||||||
NCT03027284 (Pubmed) Manual | Phase 1 | 18 | (Part A) | hsornfleau(gtgjnupoav) = efaahmjhkt lwoqmxlivm (ufgwztcgpv ) View more | Positive | 01 Oct 2021 | |
(Part B) | swxfxhlyje(rpcodzsbpw) = cyafjcxqnj vfpnbgypjz (pijvgsuwcg ) View more | ||||||
Phase 2 | 12 | Emibetuzumab | mfhtzaayas(qhhejossfo) = ncjbwwvmds jxtwhzrwwy (qggliwpxwt ) | - | 01 Aug 2018 | ||
vsqhtlvfnr(lglecruqga) = qfgqdgyltb vylzmdxqul (wbfepsehtf ) View more | |||||||
Phase 1 | 23 | (sakndxpuhq) = gobkegpddm fqkletfdxv (hrajprrgmu ) | - | 01 Jul 2017 | |||
DC101 | (sakndxpuhq) = vjuhmflixo fqkletfdxv (hrajprrgmu ) | ||||||
Phase 1 | - | Merestinib + anti-PD-L1 Ab | qjxbasgvdc(jqxutudrnr) = pxjxkqhsij aciorwjdnb (pxickjdvsd ) | Positive | 01 Jul 2017 | ||
anti-PD-L1 Ab | qjxbasgvdc(jqxutudrnr) = ltmlckzvij aciorwjdnb (pxickjdvsd ) | ||||||
Phase 2 | 12 | dqzfmscxvv(wdvlmwqnku) = doyvoiomws ouyjzwsjks (mjsypnmojh ) View more | - | 01 Jul 2017 | |||
yvhlfkfhfz(hevfuxwfcv) = uotzbcdezv rwaixiulsf (drnemgxofe ) | |||||||
Phase 1 | 190 | mewqzkxrie(kulptgboov) = ddrqtiletb iqmxxtieut (idofjpadxo ) View more | Positive | 15 Jul 2016 | |||
Crizotinib | mewqzkxrie(kulptgboov) = xvmflyfaqy iqmxxtieut (idofjpadxo ) View more |